Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Jeffrey Tate, insider at Cyclo Therapeutics

Jeffrey Tate Insider Information

Dr. Tate is a seasoned executive with more than 30 years of operations experience in the biotechnology, pharmaceutical and nutritional supplements industries including: branded generic drugs, intellectual property strategy, product development, and cGMP manufacturing. He is intimately familiar with food and drug marketing approval procedures, documentation and strategy in U.S. and foreign markets, experienced in implementation of all aspects of regulatory compliance and in successfully communicating with regulatory agency representatives.

Dr. Tate has successfully established compliant regulated manufacturing operations and integrated regulatory compliance programs resulting in timely, cost effective corporate-wide compliance, meeting regulatory agency requirements and customer expectations. He closely monitors developments in U.S. and international regulations to maintain compliance and identify regulatory and intellectual property strategies for new products and markets. He holds patents and trademarks in material processing and food formulation.

What is Jeffrey Tate's net worth?

The estimated net worth of Jeffrey Tate is at least $63,676.80 as of May 16th, 2022. Dr. Tate owns 32,160 shares of Cyclo Therapeutics stock worth more than $63,677 as of May 22nd. This net worth estimate does not reflect any other investments that Dr. Tate may own. Learn More about Jeffrey Tate's net worth.

How old is Jeffrey Tate?

Dr. Tate is currently 64 years old. There are 6 older executives and no younger executives at Cyclo Therapeutics. The oldest executive at Cyclo Therapeutics is Mr. George L. Fails, Exec. VP and Operations Mang., who is 77 years old. Learn More on Jeffrey Tate's age.

What is Jeffrey Tate's salary?

As the COO of Cyclo Therapeutics, Inc., Dr. Tate earned a total compensation package of $255,138.00 in 2020. Dr. Tate earned a salary of $195,000.00, and other compensation of $60,138.00. Learn More on Jeffrey Tate's salary.

How do I contact Jeffrey Tate?

The corporate mailing address for Dr. Tate and other Cyclo Therapeutics executives is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. Cyclo Therapeutics can also be reached via phone at (386) 418-8060 and via email at [email protected] Learn More on Jeffrey Tate's contact information.

Has Jeffrey Tate been buying or selling shares of Cyclo Therapeutics?

Within the last three months, Jeffrey Tate has bought $7,947.50 in shares of Cyclo Therapeutics stock. 0 shares of the stock in a transaction on Sunday, May 22nd. Learn More on Jeffrey Tate's trading history.

Who are Cyclo Therapeutics' active insiders?

Cyclo Therapeutics' insider roster includes Joshua Fine (CFO), N. Fine (CEO), Sharon Hrynkow (Insider), Francis Ostronic (Director), Markus Sieger (Director), and Jeffrey Tate (COO). Learn More on Cyclo Therapeutics' active insiders.

Are insiders buying or selling shares of Cyclo Therapeutics?

During the last twelve months, Cyclo Therapeutics insiders bought shares 17 times. They purchased a total of 70,754 shares worth more than $297,326.22. The most recent insider tranaction occured on May, 16th when COO Jeffrey Tate bought 3,000 shares worth more than $6,360.00. Insiders at Cyclo Therapeutics own 12.3 % of the company. Learn More about insider trades at Cyclo Therapeutics.

Information on this page was last updated on 5/16/2022.

Jeffrey Tate Insider Trading History at Cyclo Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2022Buy3,000$2.12$6,360.0032,160View SEC Filing Icon  
4/28/2022Buy635$2.50$1,587.5027,795View SEC Filing Icon  
3/29/2021Buy2,000$7.50$15,000.0027,160View SEC Filing Icon  
See Full Table

Jeffrey Tate Buying and Selling Activity at Cyclo Therapeutics

This chart shows Jeffrey Tate's buying and selling at Cyclo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclo Therapeutics Company Overview

Cyclo Therapeutics logo
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Read More

Today's Range

Now: $1.98
Low: $1.95
High: $2.10

50 Day Range

MA: $2.68
Low: $1.98
High: $3.21

2 Week Range

Now: $1.98
Low: $1.88
High: $13.00


26,605 shs

Average Volume

26,192 shs

Market Capitalization

$16.67 million

P/E Ratio


Dividend Yield



How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.